Arvinas (ARVN) Competitors $18.48 +0.65 (+3.65%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARVN vs. BBIO, CRNX, KRYS, ACLX, ADMA, RARE, APLS, BHVN, IMVT, and RNAShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Biohaven (BHVN), Immunovant (IMVT), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. BridgeBio Pharma Crinetics Pharmaceuticals Krystal Biotech Arcellx ADMA Biologics Ultragenyx Pharmaceutical Apellis Pharmaceuticals Biohaven Immunovant Avidity Biosciences BridgeBio Pharma (NASDAQ:BBIO) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking. Is BBIO or ARVN more profitable? Arvinas has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -201.53%. BridgeBio Pharma's return on equity of 0.00% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-201.53% N/A -74.34% Arvinas N/A -50.26%-24.87% Does the MarketBeat Community believe in BBIO or ARVN? Arvinas received 18 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 71.06% of users gave BridgeBio Pharma an outperform vote while only 67.03% of users gave Arvinas an outperform vote. CompanyUnderperformOutperformBridgeBio PharmaOutperform Votes16771.06% Underperform Votes6828.94% ArvinasOutperform Votes18567.03% Underperform Votes9132.97% Which has more risk & volatility, BBIO or ARVN? BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Do institutionals & insiders believe in BBIO or ARVN? 99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 24.7% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 5.2% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate BBIO or ARVN? BridgeBio Pharma presently has a consensus target price of $47.69, suggesting a potential upside of 80.04%. Arvinas has a consensus target price of $63.50, suggesting a potential upside of 243.61%. Given Arvinas' stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.86Arvinas 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has higher valuation & earnings, BBIO or ARVN? Arvinas has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$217.77M22.99-$643.20M-$2.41-10.99Arvinas$161.10M7.88-$367.30M-$4.67-3.96 Does the media prefer BBIO or ARVN? In the previous week, BridgeBio Pharma had 3 more articles in the media than Arvinas. MarketBeat recorded 10 mentions for BridgeBio Pharma and 7 mentions for Arvinas. BridgeBio Pharma's average media sentiment score of 0.90 beat Arvinas' score of 0.36 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryBridgeBio Pharma and Arvinas tied by winning 9 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23B$6.57B$5.07B$9.08BDividend YieldN/A2.97%4.87%4.21%P/E Ratio-3.9610.5999.0517.15Price / Sales7.88195.041,121.17116.80Price / CashN/A57.1641.5237.88Price / Book1.545.104.754.78Net Income-$367.30M$151.51M$119.33M$225.60M7 Day Performance-5.23%-2.13%-1.86%-1.23%1 Month Performance-26.32%-3.14%11.40%3.07%1 Year Performance-50.93%11.53%30.26%16.48% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas2.0261 of 5 stars$18.48+3.6%$63.50+243.6%-49.3%$1.23B$161.10M-3.96445High Trading VolumeBBIOBridgeBio Pharma4.6924 of 5 stars$27.86+1.3%$47.69+71.2%-30.7%$5.27B$217.77M-11.63400Positive NewsCRNXCrinetics Pharmaceuticals4.0687 of 5 stars$54.10+0.8%$70.82+30.9%+55.4%$5.02B$1.04M-14.39210Positive NewsKRYSKrystal Biotech4.5152 of 5 stars$171.83+5.0%$206.67+20.3%+45.9%$4.94B$50.70M92.45229Analyst ForecastACLXArcellx3.1314 of 5 stars$85.05+1.5%$105.93+24.5%+49.1%$4.60B$155.82M-118.03130Positive NewsADMAADMA Biologics3.7647 of 5 stars$19.13+2.9%$21.25+11.1%+325.4%$4.52B$382.81M68.32530Positive NewsGap DownRAREUltragenyx Pharmaceutical4.4437 of 5 stars$46.29+1.1%$87.46+88.9%-2.6%$4.27B$434.25M-7.081,276Analyst ForecastNews CoverageAPLSApellis Pharmaceuticals4.5591 of 5 stars$33.34+0.5%$49.94+49.8%-39.6%$4.15B$396.59M-16.35702Analyst DowngradePositive NewsBHVNBiohaven3.7042 of 5 stars$40.23+4.6%$63.00+56.6%-4.4%$4.07B$462.51M-4.11239Analyst ForecastIMVTImmunovant1.4648 of 5 stars$27.63+5.1%$47.89+73.3%-28.5%$4.06BN/A-11.84120Analyst ForecastNews CoverageRNAAvidity Biosciences2.1713 of 5 stars$33.85+4.2%$63.60+87.9%+278.8%$4.04B$10.12M-11.28190Analyst ForecastInsider TradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies BBIO Competitors CRNX Competitors KRYS Competitors ACLX Competitors ADMA Competitors RARE Competitors APLS Competitors BHVN Competitors IMVT Competitors RNA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARVN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARVN Stock Alerts